Lee, Jiyoung, Park Jinhee, Chae Jinsung, Jung Gyouchul, Yeo Changhwan
Objective: To examine the efficacy of a combination of anticancer agents and cytokine-induced killer (CIK) cell therapy in inoperable pancreato-biliary cancer patients. Methods: We retrospectively reviewed the medical records of 17 inoperable pancreato-biliary cancer patients who were hospitalized from January 2015 to December 2019 in YCH hospital, Korea, and had received at least 5 treatments with CIK-cell therapy. The patients were all on chemotherapy. The major endpoints of the investigation were the overall survival time. Results: A total of 17 patients were enrolled, 8 (47.1%) males and 9 (52.9%) females (n = 17). The mean age was 61.7 ± 7.8 years. In types of cancer, the patients of pancreatic cancer were 6, and biliary tract were 11. At the survival time analysis, 8 patients (47.1%) were still alive, but death occurred in 9 patients (52.9%). The frequency of CIK-cell therapy was 8.2 ± 4.1. The overall median survival time was 553.0 ± 129.9 days (298.4 days 807.6 days) (by Kaplan-Meier Method) which was 6-9 months longer than conventional treatment alone. Conclusion: In this study CIK-cell therapy prolonged the survival of cancer patients without any major side effects when combined with anticancer drugs. A combination of Anticancer agents with cytokine-induced killer (CIK) cell can be a good proposal for improving the treatment outcomes for pancreatic and biliary cancer. *Correspondence to: Jiyoung,Lee, Department of Family Medicine, YCH Kospital, Seoul 06605, Republic of Korea, E-mail: hello.muzzica@gmail.com
{"title":"The effect of CIK-cell therapy in combination with anticancer agents in patients with inoperable pancreato-biliary cancer","authors":"Lee, Jiyoung, Park Jinhee, Chae Jinsung, Jung Gyouchul, Yeo Changhwan","doi":"10.15761/icst.1000336","DOIUrl":"https://doi.org/10.15761/icst.1000336","url":null,"abstract":"Objective: To examine the efficacy of a combination of anticancer agents and cytokine-induced killer (CIK) cell therapy in inoperable pancreato-biliary cancer patients. Methods: We retrospectively reviewed the medical records of 17 inoperable pancreato-biliary cancer patients who were hospitalized from January 2015 to December 2019 in YCH hospital, Korea, and had received at least 5 treatments with CIK-cell therapy. The patients were all on chemotherapy. The major endpoints of the investigation were the overall survival time. Results: A total of 17 patients were enrolled, 8 (47.1%) males and 9 (52.9%) females (n = 17). The mean age was 61.7 ± 7.8 years. In types of cancer, the patients of pancreatic cancer were 6, and biliary tract were 11. At the survival time analysis, 8 patients (47.1%) were still alive, but death occurred in 9 patients (52.9%). The frequency of CIK-cell therapy was 8.2 ± 4.1. The overall median survival time was 553.0 ± 129.9 days (298.4 days 807.6 days) (by Kaplan-Meier Method) which was 6-9 months longer than conventional treatment alone. Conclusion: In this study CIK-cell therapy prolonged the survival of cancer patients without any major side effects when combined with anticancer drugs. A combination of Anticancer agents with cytokine-induced killer (CIK) cell can be a good proposal for improving the treatment outcomes for pancreatic and biliary cancer. *Correspondence to: Jiyoung,Lee, Department of Family Medicine, YCH Kospital, Seoul 06605, Republic of Korea, E-mail: hello.muzzica@gmail.com","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67477741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
conversion of to (5-HTP) and O-methyltransferase (HIOMT) which transfer of methyl group from a methyl donor to 5-HTP to form 5-MTP. very low level of 5-MTP due to expression of HIOMT. of HIOMT by stable transfection of a HIOMT isoform (HIOMT in 5-MTP production accompanied by reduced cancer cell migration in vitro and slower tumor growth and fewer lung metastatic nodules in a murine tumor model the isoforms which catalyze 5-MTP vs. melatonin biosynthesis.
{"title":"Hydroxyindole O-methyltransferase controls cancer growth and metastasis","authors":"Kenneth K. Wu","doi":"10.15761/icst.1000330","DOIUrl":"https://doi.org/10.15761/icst.1000330","url":null,"abstract":"conversion of to (5-HTP) and O-methyltransferase (HIOMT) which transfer of methyl group from a methyl donor to 5-HTP to form 5-MTP. very low level of 5-MTP due to expression of HIOMT. of HIOMT by stable transfection of a HIOMT isoform (HIOMT in 5-MTP production accompanied by reduced cancer cell migration in vitro and slower tumor growth and fewer lung metastatic nodules in a murine tumor model the isoforms which catalyze 5-MTP vs. melatonin biosynthesis.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67477514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Dallari, Federica Maroni, A. Filosa, Massimo Giuliano Bonetti
The authors report a case of Type I branchial fistula, a relatively rare lesion which requires a careful management from the diagnosis to the final surgical excision. In fact, the most frequent scenario implies one or more surgical drainages with recurrences before the proper diagnostic workout, based on an accurate examination and a RMN study. Surgical excision must take into account the risk of facial nerve injury and nowadays the standard of care recommends a magnification view and the facial nerve monitoring.
{"title":"First branchial arch anomaly: A rare lesion not to be underestimated","authors":"S. Dallari, Federica Maroni, A. Filosa, Massimo Giuliano Bonetti","doi":"10.15761/ICST.1000345","DOIUrl":"https://doi.org/10.15761/ICST.1000345","url":null,"abstract":"The authors report a case of Type I branchial fistula, a relatively rare lesion which requires a careful management from the diagnosis to the final surgical excision. In fact, the most frequent scenario implies one or more surgical drainages with recurrences before the proper diagnostic workout, based on an accurate examination and a RMN study. Surgical excision must take into account the risk of facial nerve injury and nowadays the standard of care recommends a magnification view and the facial nerve monitoring.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Paik, W. Jang, C. Park, Eunji Kim, S. Choi, S. Lee
The Organization on March 11, 2020, has declared the novel coronavirus (COVID-19) outbreak a global pandemic. As of December 29, 2020, the accumulated number of confirmed cases is over 79,600,000 with 1,760,000 deaths worldwide due to COVID-19 and these numbers rise by the day. The most effective means to minimize the spread of the virus is social distancing, which is designed to reduce the amount of interactions between individuals, according to the Centers for Disease Control. This practical working experience show our radiotherapy treatment process during the outbreak of COVID-19. We present the present work give some idea to radiation oncologists managing cancers patients with radiotherapy during the outbreak of COVID-19 in order to minimize the risks to our patients and staff while maintaining cancer outcomes.
{"title":"Practical working guideline and phantom simulation for radiotherapy during the outbreak of COVID-19 in the Republic of Korea","authors":"E. Paik, W. Jang, C. Park, Eunji Kim, S. Choi, S. Lee","doi":"10.15761/ICST.1000346","DOIUrl":"https://doi.org/10.15761/ICST.1000346","url":null,"abstract":"The Organization on March 11, 2020, has declared the novel coronavirus (COVID-19) outbreak a global pandemic. As of December 29, 2020, the accumulated number of confirmed cases is over 79,600,000 with 1,760,000 deaths worldwide due to COVID-19 and these numbers rise by the day. The most effective means to minimize the spread of the virus is social distancing, which is designed to reduce the amount of interactions between individuals, according to the Centers for Disease Control. This practical working experience show our radiotherapy treatment process during the outbreak of COVID-19. We present the present work give some idea to radiation oncologists managing cancers patients with radiotherapy during the outbreak of COVID-19 in order to minimize the risks to our patients and staff while maintaining cancer outcomes.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Benvenuto, Mariana Sgroi, S. Guillen, G. Chantada, A. Fandiño
Objective: To evaluate ophthalmological findings in patients with acute myeloid leukemia and acute lymphoblastic leukemia. Material and method: A single-center, retrospective, descriptive, observational analysis was conducted of patients with acute myeloid and acute lymphoblastic leukemia seen at the Department of Ophthalmology of Hospital de Pediatría Dr. Prof. Juan P. Garrahanin Buenos Aires, Argentina between March 1, 2017 and February 28, 2018. Results: Overall, 137 patients with acute leukemia who underwent ophthalmologic examination between March 1, 2017 and February 28, 2018 were included. Ages ranged from 0 to 18 years, with a mean of 7.9 years. Remarkably, 22.62%, i.e. more than one out of every five patients, of the cohort of patients with acute leukemia seen at our center and evaluated at the Department of Ophthalmology had some type of ocular manifestation. Conclusion: Our results show that ocular involvement occurs in a high percentage of patients with leukemia with a clear clinical, humoral, and prognostic correlation, suggesting that ophthalmologic evaluation should be routinely performed in these patients.
{"title":"Ophthalmologic manifestations in Acute Leukemia","authors":"F. Benvenuto, Mariana Sgroi, S. Guillen, G. Chantada, A. Fandiño","doi":"10.15761/icst.1000327","DOIUrl":"https://doi.org/10.15761/icst.1000327","url":null,"abstract":"Objective: To evaluate ophthalmological findings in patients with acute myeloid leukemia and acute lymphoblastic leukemia. Material and method: A single-center, retrospective, descriptive, observational analysis was conducted of patients with acute myeloid and acute lymphoblastic leukemia seen at the Department of Ophthalmology of Hospital de Pediatría Dr. Prof. Juan P. Garrahanin Buenos Aires, Argentina between March 1, 2017 and February 28, 2018. Results: Overall, 137 patients with acute leukemia who underwent ophthalmologic examination between March 1, 2017 and February 28, 2018 were included. Ages ranged from 0 to 18 years, with a mean of 7.9 years. Remarkably, 22.62%, i.e. more than one out of every five patients, of the cohort of patients with acute leukemia seen at our center and evaluated at the Department of Ophthalmology had some type of ocular manifestation. Conclusion: Our results show that ocular involvement occurs in a high percentage of patients with leukemia with a clear clinical, humoral, and prognostic correlation, suggesting that ophthalmologic evaluation should be routinely performed in these patients.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67477256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The incidence of ovarian tumor in pregnancy is quite rare approximating to 1 in 190 pregnancies. Scanty evidence is available for the treatment of this condition due to lack of RCTs and cohort studies. However, only 1-6 % of ovarian tumors are reported to be malignant in nature during pregnancy. We report 6 cases of ovarian malignancies which depicts the difficulty of making this rare diagnosis along with their brief clinical presentation, diagnosis and therapeutic approach. The findings from these cases describe the interventions which ameliorates patients’ quality of life. *Correspondence to: Harsha Khullar, Vice-Chairperson& Senior Consultant, Institute of Obstetrics & Gynecology, Sir Ganga Ram Hospital, New Delhi, India, E-mail: harsha_khullar@yahoo.com Received: May 25, 2020; Accepted: June 16, 2020; Published: June 19, 2020 Key points • Ovarian tumor is the fifth most common cancer • Only 3 to 5% of ovarian tumors in pregnancy are malignant. • Signs and symptoms include incidental finding, abdominal or back pain. • High levels of Maternal Serum AFP, Inhibin A obtained during aneuploidy screening can be a sign of GCT • Adequate surgical staging is important for stage I cancer. • Ideal time for surgery is in second trimester of pregnancy • Treatment in each case should be individualized • Chemotherapy can be given antenatally but with prior consents.
妊娠期卵巢肿瘤的发生率非常罕见，约为1 / 190。由于缺乏随机对照试验和队列研究，治疗这种疾病的证据很少。然而，据报道，只有1- 6%的卵巢肿瘤在怀孕期间是恶性的。我们报告了6例卵巢恶性肿瘤，描述了这种罕见诊断的困难，以及它们的简短临床表现，诊断和治疗方法。这些病例的发现描述了改善患者生活质量的干预措施。*通讯对象:印度新德里Sir Ganga Ram医院妇产科研究所副主任兼高级顾问Harsha Khullar, E-mail: harsha_khullar@yahoo.com录用日期:2020年6月16日;•卵巢肿瘤是第五大常见癌症•妊娠期卵巢肿瘤中只有3%至5%是恶性的。•体征和症状包括意外发现，腹部或背部疼痛。•在非整倍体筛查中获得的高水平的母体血清AFP，抑制素A可能是GCT的征兆•对于I期癌症，适当的手术分期是重要的。•手术的理想时间是在妊娠中期•每种情况下的治疗应该是个体化的•化疗可以在产前进行，但必须事先征得同意。
{"title":"Ovarian tumor diagnosed during pregnancy & their management","authors":"Harsha Khullar, G. Mediratta, S. Garg","doi":"10.15761/icst.1000338","DOIUrl":"https://doi.org/10.15761/icst.1000338","url":null,"abstract":"The incidence of ovarian tumor in pregnancy is quite rare approximating to 1 in 190 pregnancies. Scanty evidence is available for the treatment of this condition due to lack of RCTs and cohort studies. However, only 1-6 % of ovarian tumors are reported to be malignant in nature during pregnancy. We report 6 cases of ovarian malignancies which depicts the difficulty of making this rare diagnosis along with their brief clinical presentation, diagnosis and therapeutic approach. The findings from these cases describe the interventions which ameliorates patients’ quality of life. *Correspondence to: Harsha Khullar, Vice-Chairperson& Senior Consultant, Institute of Obstetrics & Gynecology, Sir Ganga Ram Hospital, New Delhi, India, E-mail: harsha_khullar@yahoo.com Received: May 25, 2020; Accepted: June 16, 2020; Published: June 19, 2020 Key points • Ovarian tumor is the fifth most common cancer • Only 3 to 5% of ovarian tumors in pregnancy are malignant. • Signs and symptoms include incidental finding, abdominal or back pain. • High levels of Maternal Serum AFP, Inhibin A obtained during aneuploidy screening can be a sign of GCT • Adequate surgical staging is important for stage I cancer. • Ideal time for surgery is in second trimester of pregnancy • Treatment in each case should be individualized • Chemotherapy can be given antenatally but with prior consents.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67477967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Received: April 04, 2020; Accepted: April 14, 2020; Published: April 17, 2020 The number of new cancer diagnoses is projected to increase by over 20% in Europe by 2035, and cancer is expected to become the leading cause of death worldwide. Accepted risk factors for cancer include smoking, alcohol consumption, diet (insufficient consumption of fruit, vegetables, fiber, and dairy products and consumption of red and processed meat), obesity, and lack of physical activity. Pancreatic cancers, about 85% of which are pancreatic ductal adenocarcinomas, are highly lethal, with a 5-year survival rate of only 7% [1]. A greater understanding of the risk factors for pancreatic cancer are urgently required to develop preventative and early detection strategies.
{"title":"Non-hereditary risk factors associated with pancreatic cancer: a focus on obesity and diabetes","authors":"C. Tiffon","doi":"10.15761/icst.1000335","DOIUrl":"https://doi.org/10.15761/icst.1000335","url":null,"abstract":"Received: April 04, 2020; Accepted: April 14, 2020; Published: April 17, 2020 The number of new cancer diagnoses is projected to increase by over 20% in Europe by 2035, and cancer is expected to become the leading cause of death worldwide. Accepted risk factors for cancer include smoking, alcohol consumption, diet (insufficient consumption of fruit, vegetables, fiber, and dairy products and consumption of red and processed meat), obesity, and lack of physical activity. Pancreatic cancers, about 85% of which are pancreatic ductal adenocarcinomas, are highly lethal, with a 5-year survival rate of only 7% [1]. A greater understanding of the risk factors for pancreatic cancer are urgently required to develop preventative and early detection strategies.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of this paper is to assess the cost-effectivess of regorafenib and cabozantib in the treatment of advanced hepatocellular carcinoma (HCC) after sorafenib. Pivotal phase III randomized controlled trials (RCTs) were considered. Incremental cost-effectiveness ratio (ICER) was calculated for both treatments. Two phase III RCTs, including 1274 patients, were considered. Regorafenib resulted the less expensive, with 2771 € per month overall survival (OS)-gained versus 5309 € of cabozantinib. Combining pharmacological costs of drugs with the measure of efficacy represented by the OS, regorafenib is a cost-effective for the treatment of advanced HCC after sorafenib.
{"title":"Regorafenib or Cabozantinib in second or subsequent lines after Sorafenib in advanced hepatocellular carcinoma. Which way to chose?","authors":"J. Giuliani, F. Fiorica, A. Bonetti","doi":"10.15761/ICST.1000344","DOIUrl":"https://doi.org/10.15761/ICST.1000344","url":null,"abstract":"The aim of this paper is to assess the cost-effectivess of regorafenib and cabozantib in the treatment of advanced hepatocellular carcinoma (HCC) after sorafenib. Pivotal phase III randomized controlled trials (RCTs) were considered. Incremental cost-effectiveness ratio (ICER) was calculated for both treatments. Two phase III RCTs, including 1274 patients, were considered. Regorafenib resulted the less expensive, with 2771 € per month overall survival (OS)-gained versus 5309 € of cabozantinib. Combining pharmacological costs of drugs with the measure of efficacy represented by the OS, regorafenib is a cost-effective for the treatment of advanced HCC after sorafenib.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancers are the second leading cause of death after cardiovascular diseases in industrialized countries, so there is an urgent need to deepen the knowledge of the metabolism and the microenvironment of cancer cells. In fact, new efficient therapeutic approaches are emerged in order to produce the energy required for blocking their proliferation, migration and metastasis. Cancer cells and host cells can use different bioenergetic fuels exchanged across plasma membranes via a special gate called Monocarboxylate Transporters (MCTs), passive transporters that ensure a bidirectional exchange depending on the concentration gradient of their substrates. Two MCT isoforms have been extremely studied and mainly expressed in different cancer cells called MCT1 and MCT4 [1]. Since MCTs gate the activity of different bioenergetics fuels, a new strategy for anticancer treatments will be to target them with specific drugs in the form of MCT inhibitors. Pr. Pierre Sonveaux team are still working on the characterization and the development of these anti-cancer strategies [2].
{"title":"A better understanding of cancer metabolism for a more efficient immunotherapy","authors":"D. Bensaid, K. Raghay, C. Blanquart","doi":"10.15761/icst.1000331","DOIUrl":"https://doi.org/10.15761/icst.1000331","url":null,"abstract":"Cancers are the second leading cause of death after cardiovascular diseases in industrialized countries, so there is an urgent need to deepen the knowledge of the metabolism and the microenvironment of cancer cells. In fact, new efficient therapeutic approaches are emerged in order to produce the energy required for blocking their proliferation, migration and metastasis. Cancer cells and host cells can use different bioenergetic fuels exchanged across plasma membranes via a special gate called Monocarboxylate Transporters (MCTs), passive transporters that ensure a bidirectional exchange depending on the concentration gradient of their substrates. Two MCT isoforms have been extremely studied and mainly expressed in different cancer cells called MCT1 and MCT4 [1]. Since MCTs gate the activity of different bioenergetics fuels, a new strategy for anticancer treatments will be to target them with specific drugs in the form of MCT inhibitors. Pr. Pierre Sonveaux team are still working on the characterization and the development of these anti-cancer strategies [2].","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67477654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this review, we have focused on immune restoration after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and solid organ transplantations (SOT). We discuss the kinetics of cytokine secretion during immune reconstitution phases that play a unique role in the connection between innate and adaptive immunity, therefore essential in normal and pathological immune reconstitution. We overview the importance of T cell immunity for antigen-specific immune reconstitution and the production of cytokines. We briefly touch upon a graft versus host disease and other immunopathology that accompany poor immune restoration after transplantation and discuss therapeutic interventions. *Correspondence to: Irina Vlasova-St. Louis, Department of Medicine, University of Minnesota, Minneapolis, MN, USA, E-mail: irinastl@umn.edu
{"title":"Kinetics of immune reconstitution and immune complications after cell and organ transplantation","authors":"Usha Kellampalli, Hesham Mohei, I. S. Louis","doi":"10.15761/icst.1000341","DOIUrl":"https://doi.org/10.15761/icst.1000341","url":null,"abstract":"In this review, we have focused on immune restoration after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and solid organ transplantations (SOT). We discuss the kinetics of cytokine secretion during immune reconstitution phases that play a unique role in the connection between innate and adaptive immunity, therefore essential in normal and pathological immune reconstitution. We overview the importance of T cell immunity for antigen-specific immune reconstitution and the production of cytokines. We briefly touch upon a graft versus host disease and other immunopathology that accompany poor immune restoration after transplantation and discuss therapeutic interventions. *Correspondence to: Irina Vlasova-St. Louis, Department of Medicine, University of Minnesota, Minneapolis, MN, USA, E-mail: irinastl@umn.edu","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67477776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：